Exelixis
Manufacturing · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1851 Harbor Bay Pkwy, Alameda, Californi...Phone Number
(650) 837-7000Website
www.exelixis.comRevenue
$2.4 BillionStock Symbol
EXELIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
1
1
1
About Exelixis
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.Explore more
Exelixis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Exelixis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Exelixis, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Exelixis recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Exelixis
Check if Exelixis has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Exelixis has new funding data
Check out if Exelixis is spiking on competitors!
Product Launch: Get notified when Exelixis launches new products
Click to see if Exelixis had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Exelixis
Find 3 more new buyers
Compare Similar Companies to Exelixis
Compare insights from companies similar to Exelixis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Exelixis
$2.4B
1K - 5K
Public
$118.3M
1994
Christopher SennerExecutive Vice President & Chief Financial Officer
Company Profile Activity
Activity Insights
Exelixis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Exelixis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Exelixis.
Exelixis financials insights
Gather financial insights about Exelixis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2000
Stock Offering
$118.3M
Exelixis Tech Stack
A closer look at the technologies used by Exelixis
See more technologies
Most Recent Scoops
Pain Point
Exelixis is facing a potential intellectual property and patient safety challenge related to a 505(b)(2) application for a different salt of cabozantinib, which Exelixis notes has very different pharmacokinetic properties and lacks the clinical data comparable to established 505(b)(2) examples such as ABRAXANE. Exelixis has stated it is focused on patient safety and prioritizing its intellectual property rights in response to this development.
Intellectual Property, Legal Affairs, Patient Experience
Earnings
Exelixis has reported GAAP net income of approximately $212 million, or $0.85 per share basic and $0.82 per share diluted, for Q2 2026. Exelixis also reported non-GAAP net income of approximately $237 million, or $0.95 per share basic and $0.91 per share fully diluted, excluding approximately $25 million of stock-based compensation net of the related income tax effect.
Earnings, Finance
Open Position
Open Position
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Exelixis News & Media
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Exelixis, Inc. (EXEL) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 11:00 AM EDTCompany ParticipantsAndrew Peters - Senior Vice President...Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing....Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating. NEW YORK, Aug. 17, 2026 /PRNewswire/ -- A revenue miss, not an earnings miss, drove Exelixis, Inc....
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Exelixis
Sign Up For FreeTo access detailed company insights
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatm... Read More
